An agreement signed between South Korea’s SK Group and the company founded by Bill Gates that is developing a new generation nuclear power reactor includes the potential production of radioisotopes for medical applications.
TerraPower said in an email seen by NucNet that its agreement with SK subsidiaries SK Inc and SK Innovation, signed on 17 May, is in support of commercialising advanced reactor technologies.
The email also said the groups will also explore opportunities between TerraPower’s medical isotopes production capabilities and SK Group’s biopharmaceutical investment portfolio.
TerraPower said in an email seen by NucNet that its agreement with SK subsidiaries SK Inc and SK Innovation, signed on 17 May, is in support of commercialising advanced reactor technologies.
The email also said the groups will also explore opportunities between TerraPower’s medical isotopes production capabilities and SK Group’s biopharmaceutical investment portfolio.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
